Rankings / Longevity — Senolytics & Polyphenols

Senolytics (D+Q combo)

Longevity · Senolytic

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

senolyticpolyphenolanti-inflammatoryprescription
5.5 / 10
Tier C+
Ev 6 Bn 5 Sf 5

Bottom line

Read Off Label grades Senolytics (D+Q combo) as C+ (5.5/10) based on moderate evidence, variable benefit magnitude, and a med-risk safety profile.

First-ever senolytic human trials (Justice 2019, Hickson 2019).

Studied, labeled, or reported-use context: D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple… — Rx; not individualized guidance.

Frontier potential — editorial judgment, not evidence

This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.

7/10
Large effect, narrow evidence Phase 2

What the ceiling rests on

Clearing senescent cells extended healthspan and median lifespan in mice and reversed specific age-related pathologies. Early human trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed condition-specific functional improvement and confirmed senescent-cell clearance in human tissue, which is a real translational step most of this field has not reached.

Why it may not get there

Human results are small, condition-specific, and unblinded in places; the intermittent dosing schedule is inferred from mouse work rather than established in people. Dasatinib is a chemotherapy agent with real toxicity, and senescent cells have beneficial roles in wound healing and tumour suppression that broad clearance may compromise.

What would change this A randomised placebo-controlled trial in an ageing (rather than disease) population.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Slow to reverse

The intermittent schedule means exposure is brief, but dasatinib is a chemotherapy agent with real acute toxicity, and cleared senescent cells do not come back — which is the point, and also means the intervention is not undone by stopping.

Can you tell if it worked?

Nothing you can measure

No endpoint exists that you could observe for the reason this is taken. An experiment without a readout cannot tell you anything, however it turns out.

What would fool you No endpoint exists that a person could read. The human trials used tissue senescence markers and disease-specific function tests, neither of which is available outside a study.

What the evidence says

First-ever senolytic human trials (Justice 2019, Hickson 2019). Reduced senescent cell markers in adipose tissue; improved physical function in IPF. Epigenetic clock data mixed. Long-term safety in healthy adults unknown.

Mechanism

Dasatinib (BCR-ABL/Src inhibitor) + Quercetin (flavonoid) selectively kill senescent cells by disabling pro-survival SCAP pathways; cleared SnCs reduce SASP inflammation

Studied, labeled, or reported dose & route

D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple cycles

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Senolytics (D+Q combo)'s effects?
Read Off Label rates the evidence for Senolytics (D+Q combo) as Moderate and the benefit magnitude as variable, producing an overall grade of C+ (5.5/10). First-ever senolytic human trials (Justice 2019, Hickson 2019).
What safety findings are reported for Senolytics (D+Q combo)?
Senolytics (D+Q combo) has a med risk profile in the database. Med (dasatinib has oncology side effect profile: GI, hematologic; intermittent dosing mitigates) Legal status: Rx (dasatinib is oncology drug — off-label use).
What doses or routes are reported for Senolytics (D+Q combo)?
D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple cycles This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Senolytics (D+Q combo) work?
Dasatinib (BCR-ABL/Src inhibitor) + Quercetin (flavonoid) selectively kill senescent cells by disabling pro-survival SCAP pathways; cleared SnCs reduce SASP inflammation

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.